Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but ...

Shares of Dr Reddy's Laboratories Ltd tumbled more than 6.65 per cent to Rs 1,203.60 on Friday, with its total market capitalisation slipping below Rs 1 lakh crore mark.

Dr Reddy’s shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE).

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

The long-term prospects for the company are evolving with product approvals in China, build-up of consumer healthcare franchise, and a biosimilar pipeline.

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

A viral video from a northeast Indianapolis gas station shows a man pointing a handgun in a woman's face and shoving her up against a car while threatening her. Police have since arrested the man on ...

Three businesses on Chicago's Northwest Side were burglarized early Thursday morning. Now, one of the shop's owners is speaking out.

Ozempic is well-known for its ability to manage type 2 diabetes and aid weight loss. . But as more research emerges, additional health benefits of the GLP-1 drug are being uncovered. Previous studies ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Semaglutide is a powerful aid for managing weight and Type 2 diabetes, but it’s not a free pass to stick with old habits—or skip taking action altogether. If you’ve been struggling with weight loss, ...

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March ...